NYQ – Цена в реальном времени. Валюта: USD
119.63
+0.70 (0.59%)
При закрытии: Mar 27, 2026, 4:00 PM EDT
119.26
-0.37 (-0.31%)
После закрытия: Mar 27, 2026, 7:59 PM EDT
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo’s deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca’s Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
| Имя | Должность |
|---|---|
| Dr. Dean Y. Li M.D., Ph.D. | Executive VP & President of Merck Research Laboratories |
| Mr. Chirfi Guindo | Executive Vice President of Strategic Access, Policy & Communications |
| Mr. Dalton E. Smart III | Senior VP of Finance, Principal Accounting Officer & Global Controller |
| Mr. David Michael Williams | Executive VP and Chief Information & Digital Officer |
| Mr. Peter Dannenbaum | Vice President of Investor Relations |
| Mr. Richard R. DeLuca Jr. | Executive VP & President of Merck Animal Health |
| Mr. Robert M. Davis J.D. | Chairman, President & CEO |
| Дата | Тип | Документ |
|---|---|---|
| 2026-02-03 | 8-K | tm264564d1_8k.htm |
| 2025-12-04 | 8-K | mrk-20251204.htm |
| 2025-11-05 | 10-Q | mrk-20250930.htm |
| 2025-10-30 | 8-K | tm2529620d1_8k.htm |
| 2025-09-11 | DFAN14A | d69140ddfan14a.htm |
| 2025-09-09 | 8-K | mrk-20250909.htm |
| 2025-08-05 | 10-Q | mrk-20250630.htm |
| 2025-07-30 | DFAN14A | d69221ddfan14a.htm |
| 2025-07-29 | 8-K | tm2521736d1_8k.htm |
| 2025-07-09 | DFAN14A | d946997ddfan14a.htm |
| Ms. Betty D. Larson | Executive VP & Chief Human Resources Officer |
| Ms. Caroline A. Litchfield | Executive VP & CFO |
| Ms. Jennifer L. Zachary J.D. | Executive VP & General Counsel |